Abstract
Pituitary adenylate cyclase activating polypeptide (PACAP) is a neuropeptide with wide distribution and diverse effects. Its presence has not only been revealed in the nervous system and peripheral organs, but also in the blood and other biological fluids. Although PACAP is rapidly cleaved in the blood by peptidases, increasing number of evidence has been published in the last 10 years that show alterations of PACAP levels in different pathological conditions. The present review summarizes results obtained in the human blood and other fluids under normal, physiological and pathological conditions with clinical relevance, such as pregnancy and delivery, as well as in several diseases. Most clinical data have been obtained so far in neurological diseases, such as Alzheimer’s disease, migraine, traumatic brain injury, multiple sclerosis, and cerebral hemorrhage, but some other diseases have also been shown to be accompanied by alterations of PACAP levels. These results indicate that the altered levels may have diagnostic and/or prognostic values in several diseases.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Edvinsson L, Ekman R, Goadsby PJ. Measurement of vasoactive neuropeptides in biological materials: problems and pitfalls from 30 years of experience and novel future approaches. Cephalalgia. 2010;30:761–6.
Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, et al. Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun. 1989;164:567–74.
Palkovits M, Somogyvari-Vigh A, Arimura A. Concentrations of pituitary adenylate cyclase activating polypeptide (PACAP) in human brain nuclei. Brain Res. 1995;699:116–20.
Warren JB, Cockcroft JR, Larkin SW, Kajekar R, Macrae A, Ghatei MA, et al. Pituitary adenylate cyclase activating polypeptide is a potent vasodilator in humans. J Cardiovasc Pharmacol. 1992;20:83–7.
Freson K, Hashimoto H, Thys C, Wittevrongel C, Danloy S, Morita Y, et al. The pituitary adenylate cyclase-activating polypeptide is a physiological inhibitor of platelet activation. J Clin Invest. 2004;113:905–12.
Li M, Maderdrut JL, Lertora JJ, Batuman V. Intravenous infusion of pituitary adenylate cyclase-activating polypeptide (PACAP) in a patient with multiple myeloma and myeloma kidney: a case study. Peptides. 2007;28:1891–5.
Hansen JM, Fahrenkrug J, Petersen J, Wienecke T, Olsen KS, Ashina M. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) in the circulation after sumatriptan. Scand J Pain. 2013;4:211–6.
Birk S, Sitarz JT, Petersen KA, Oturai PS, Kruuse C, Fahrenkrug J, et al. The effect of intravenous PACAP38 on cerebral hemodynamics in healthy volunteers. Regul Pept. 2007;140:185–91.
Doberer D, Gschwandtner M, Mosgoeller W, Bieglmayer C, Heinzl H, Petkov V. Pulmonary and systemic effects of inhaled PACAP38 in healthy male subjects. Eur J Clin Invest. 2007;37:665–72.
Reglodi D, Gyarmati J, Ertl T, Borzsei R, Bodis J, Tamas A, et al. Alterations of pituitary adenylate cyclase-activating polypeptide-like immunoreactivity in the human plasma during pregnancy and after birth. J Endocrinol Invest. 2010;33:443–5.
Kanasaki H, Purwana IN, Oride A, Mijiddorj T, Sukhbaatar U, Miyazaki K. Circulating kisspeptin and pituitary adenylate cyclase-activating polypeptide (PACAP) do not correlate with gonadotropin serum levels. Gynecol Endocrinol. 2013;29:583–7.
Winters SJ, King JC, Brees CK, Moore Jr JP. Pituitary adenylate cyclase-activating polypeptide (PACAP) in fetal cord blood. Early Hum Dev. 2014;90:451–3.
Amin FM, Hougaard A, Schytz HW, Asghar MS, Lundholm E, Parvaiz AI, et al. Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain. 2014;137:779–94.
Ma BQ, Zhang M, Ba L. Plasma pituitary adenylate cyclase-activating polypeptide concentrations and mortality after acute spontaneous basal ganglia hemorrhage. Clin Chim Acta. 2015;439:102–6.
Jiang L, Wang WH, Dong XQ, Yu WH, Du Q, Yang DB, et al. The change of plasma pituitary adenylate cyclase-activating polypeptide levels after aneurysmal subarachnoid hemorrhage. Acta Neurol Scand. 2016;197:35–42.
Han P, Liang W, Baxter LC, Yin J, Tang Z, Beach TG, et al. Pituitary adenylate cyclase-activating polypeptide is reduced in Alzheimer disease. Neurology. 2014;82:1724–8.
Han P, Tang Z, Yin J, Maalouf M, Beach TG, Reiman EM, et al. Pituitary adenylate cyclase-activating polypeptide protects against β-amyloid toxicity. Neurobiol Aging. 2014;35:2064–71.
Han P, Caselli RJ, Baxter L, Serrano G, Yin J, Beach TG, et al. Association of pituitary adenylate cyclase-activating polypeptide with cognitive decline in mild cognitive impairment due to Alzheimer disease. JAMA Neurol. 2015;72:333–9.
Nelson KB, Grether JK, Croen LA, Dambrosia JM, Dickens BF, Jelliffe LL, et al. Neuropeptides and neurotrophins in neonatal blood of children with autism or mental retardation. Ann Neurol. 2001;49:597–606.
Tuka B, Helyes Z, Markovics A, Bagoly T, Szolcsanyi J, et al. Alterations in PACAP38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia. 2013;33:1085–95.
Zagami AS, Edvinsson L, Goadsby PJ. Pituitary adenylate cyclase activating polypeptide and migraine. Ann Clin Transl Neurol. 2014;1:1036–40.
Baranowska-Bik A, Kochanowski J, Uchman D, Wolinska-Witort E, Kalisz M, Martynska L, et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) in humans with multiple sclerosis. J Neuroimmunol. 2013;263:159–61.
Ressler KJ, Mercer KB, Bradley B, Jovanovic T, Mahan A, Kerley K, et al. Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature. 2011;470:492–7.
Bukovics P, Czeiter E, Amrein K, Kovacs N, Pal J, Tamas A, et al. Changes of PACAP level in cerebrospinal fluid and plasma of patients with severe traumatic brain injury. Peptides. 2014;60:18–22.
Elefsiniotis IS, Ketikoglou I, Kafiri G, Pantazis KD, Moulakakis A, Mavrogiannis C. Plasma pituitary adenylate cyclase activating polypeptide (PACAP) levels in chronic hepatitis B patients under lamivudine treatment. Eur J Gastroenterol Hepatol. 2003;15:1209–16.
Eneman B, Freson K, van den Heuvel L, van Hoyweghen E, Collard L, Vande Walle J, et al. Pituitary adenylate cyclase-activating polypeptide deficiency associated with increased platelet count and aggregability in nephrotic syndrome. J Thromb Haemost. 2015;13:755–67.
Koppan M, Varnagy A, Reglodi D, Brubel R, Nemeth J, Tamas A, et al. Correlation between oocyte number and follicular fluid concentration of pituitary adenylate cyclase-activating polypeptide (PACAP) in women after superovulation treatment. J Mol Neurosci. 2012;48:617–22.
Dow RC, Bennie J, Fink G. Pituitary adenylate cyclase-activating peptide-38 (PACAP)-38 is released into hypophysial portal blood in the normal male and female rat. J Endocrinol. 1994;142:R1–4.
Brubel R, Reglodi D, Jambor E, Koppan M, Varnagy A, Biro Z, et al. Investigation of pituitary adenylate cyclase activating polypeptide in human gynecological and other biological fluids by using MALDI TOF mass spectrometry. J Mass Spectrom. 2011;46:189–94.
Borzsei R, Mark L, Tamas A, Bagoly T, Bay C, Csanaky K, et al. Presence of pituitary adenylate cyclase activating polypeptide-38 in human plasma and milk. Eur J Endocrinol. 2009;160:561–5.
Wu ZL, Ciallella JR, Flood DG, O'Kane TM, Bozyczko-Coyne D, Savage MJ. Comparative analysis of cortical gene expression in mouse models of Alzheimer’s disease. Neurobiol Aging. 2006;27:377–86.
van Landeghem FK, Weiss T, Oehmichen M, von Deimling A. Cellular localization of pituitary adenylate cyclase-activating peptide (PACAP) following traumatic brain injury in humans. Acta Neuropathol. 2007;113:683–93.
Kato H, Ito A, Kawanokuchi J, Jin S, Mizuno T, Ojika K, et al. Pituitary adenylate cyclase-activating polypeptide (PACAP) ameliorates experimental autoimmune encephalomyelitis by suppressing the functions of antigen presenting cells. Mult Scler. 2004;10:651–9.
Tan YV, Abad C, Wang Y, Lopez R, Waschek JA. VPAC2 (vasoactive intestinal peptide receptor type 2) receptor deficient mice develop exacerbated experimental autoimmune encephalomyelitis with increased Th1/Th17 and reduced Th2/Treg responses. Brain Behav Immun. 2015;44:167–75.
Tan YV, Waschek JA. Targeting VIP and PACAP receptor signalling: new therapeutic strategies in multiple sclerosis. ASN Neuro. 2011;3(4):e00065.
Vecsei L, Tuka B, Tajti J. Role of PACAP in migraine headaches. Brain. 2014;137:650–1.
Schytz HW, Birk S, Wienecke T, Kruuse C, Olesen J, Ashina M. PACAP38 induces migraine-like attacks in patients with migraine without aura. Brain. 2009;132:16–25.
Tuka B, Helyes Z, Markovics A, Bagoly T, Nemeth J, Mark L, et al. Peripheral and central alterations of pituitary adenylate cyclase activating polypeptide-like immunoreactivity in the rat in response to activation of the trigeminovascular system. Peptides. 2012;33:307–16.
Markovics A, Kormos V, Gaszner B, Lashgarara A, Szoke E, Sandor K, et al. Pituitary adenylate cyclase-activating polypeptide plays a key role in nitroglycerol-induced trigeminovascular activation in mice. Neurobiol Dis. 2012;45:633–44.
Tajti J, Tuka B, Botz B, Helyes Z, Vecsei L. Role of pituitary adenylate cyclase-activating polypeptide in nociception and migraine. CNS Neurol Disord Drug Targets. 2015;14:540–53.
Tajti J, Szok D, Majlath Z, Tuka B, Csati A, Vecsei L. Migraine and neuropeptides. Neuropeptides. 2015;52:19–30.
Somogyvari-Vigh A, Reglodi D. Pituitary adenylate cyclase activating polypeptide: a potential neuroprotective peptide. Curr Pharm Des. 2004;10:2861–89. Review.
Nemeth J, Reglodi D, Pozsgai G, Szabo A, Elekes K, Pinter E, et al. Effect of pituitary adenylate cyclase activating polypeptide-38 on sensory neuropeptide release and neurogenic inflammation in rats and mice. Neuroscience. 2006;143:223–30.
Steinhoff M, McGregor GP, Radleff-Schlimme A, Steinhoff A, Jarry H, Schmidt WE. Identification of pituitary adenylate cyclase activating polypeptide (PACAP) and PACAP type 1 receptor in human skin: expression of PACAP38 is increased in patients with psoriasis. Regul Pept. 1999;80:49–55.
Szanto Z, Sarszegi Z, Reglodi D, Nemeth J, Szabadfi K, Kiss P, et al. PACAP immunoreactivity in human malignant tumor samples and cardiac diseases. J Mol Neurosci. 2012;48:667–73.
Tamas A, Javorhazy A, Reglodi D, Sarlos DP, Banyai D, Semjen D, et al. Examination of PACAP-like immunoreactivity in urogenital tumor samples. J Mol Neurosci. 2015;2015:PMID:26454744.
Wojtkiewicz J, Jana B, Kozłowska A, Crayton R, Majewski M, Zalecki M, et al. Innervation pattern of polycystic ovaries in the women. J Chem Neuroanat. 2014;6162:147–52.
Chan MK, Gottschalk MG, Haenisch F, Tomasik J, Ruland T, Rahmoune H, et al. Applications of blood-based protein biomarker strategies in the study of psychiatric disorders. Prog Neurobiol. 2014;122:45–72.
Tams JW, Johnsen AH, Fahrenkrug J. Identification of pituitary adenylate cyclase-activating polypeptide1-38-binding factor in human plasma, as ceruloplasmin. Biochem J. 1999;341:271–6.
Bourgault S, Vaudry D, Botia B, Couvineau A, Laburthe M, Vaudry H, et al. Novel stable PACAP analogs with potent activity towards the PAC1 receptor. Peptides. 2008;29:919–32.
Acknowledgements
This study was supported by the following grants: OTKA K104984, 115874, 119759, Arimura Foundation, TAMOP 4.2.4.A/2-11-1-2012-0001 “National Excellence Program”, New National Excellence Program (UNKP), Janos Bolyai Research Scholarship of Hungarian Academy of Sciences, MTA-PTE “Lendulet” Program, PTE AOK KA Research Grant, and the National Brain Research Programmes A and B (KTIA_NAP_13-2014-0022 and KTIA_13_NAP-A-III/5, Research site ID number: 888819, Hungary). This work is dedicated to the 650th anniversary of the University of Pecs.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Reglodi, D., Helyes, Z., Nemeth, J., Vass, R.A., Tamas, A. (2016). PACAP as a Potential Biomarker: Alterations of PACAP Levels in Human Physiological and Pathological Conditions. In: Reglodi, D., Tamas, A. (eds) Pituitary Adenylate Cyclase Activating Polypeptide — PACAP. Current Topics in Neurotoxicity, vol 11. Springer, Cham. https://doi.org/10.1007/978-3-319-35135-3_48
Download citation
DOI: https://doi.org/10.1007/978-3-319-35135-3_48
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-35133-9
Online ISBN: 978-3-319-35135-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)